Clinical trial
Haploidentical Allogeneic Hematopoietic Stem Cell Transplantation With Post-transplant Cyclophosphamide in Patients With Acquired Refractory Aplastic Anemia or in Relapse After Immunosuppression: a Nationwide Phase II Study
NCT05126849 is registered in ClinicalTrials.gov with Assistance Publique - Hôpitaux de Paris as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Haploidentical Allogeneic Hematopoietic Stem Cell Transplantation With Post-transplant Cyclophosphamide in Patients With Acquired Refractory Aplastic Anemia or in Relapse After Immunosuppression: a Nationwide Phase II Study
- Lead sponsor
- Assistance Publique - Hôpitaux de Paris
- Phase
- Phase 2
- Overall status
- Recruiting
- Start date
- January 6, 2022
- Completion date
- January 6, 2027
- Enrollment
- 31 (estimated)
- Sites
- 35
Conditions
As the registry lists them; a condition with its own page is linked.
haploidentical allogeneic hematopoietic stem cell transplantation, refractory idiopathic aplastic anemia